Core Viewpoint - Johnson & Johnson reported a 9% revenue growth in the fourth quarter, driven by strong performance in its cancer drug segment [1] Group 1: Revenue Performance - The company achieved a revenue increase of 9% in the fourth quarter [1] - The growth was primarily attributed to the strength of its cancer drugs [1] Group 2: Product Performance - Cancer drugs played a significant role in the revenue growth, indicating robust demand in this therapeutic area [1]

Core Brand Group Strategy - The core brand group of Volkswagen plans to reduce management positions and consolidate its platform to achieve cost savings of 1 billion euros ($1.2 billion) [1]

Core Insights - The medical technology (medtech) sales for 2025 are projected to reach $33.79 billion, reflecting a year-over-year growth of 6.1% [1] - The cardiovascular segment of Johnson & Johnson (J&J) is a significant driver of this growth, with sales totaling $8.93 billion and a year-over-year increase of 15.8% [1][4] - The orthopedic segment, in contrast, has shown minimal growth of 1.1% year over year [1] Group 1: Cardiovascular Business Performance - J&J's cardiovascular business, which includes units like Abiomed and Shockwave Medical, experienced double-digit growth year over year, making it the only medtech unit to achieve such growth [2] - The strong performance in the cardiovascular segment is part of J&J's strategy to focus on higher growth markets, leading to the decision to separate from its orthopedics segment [2] Group 2: Portfolio Transformation and Future Outlook - Tim Schmid, J&J's worldwide chairman of medtech, indicated that the transformation of the portfolio is effective, with nearly 50% of J&J's medtech assets now in higher growth markets, up from 20% in 2018 [3] - This percentage is expected to exceed 70% following the orthopedic separation, suggesting a positive outlook for the company's future growth [3] Group 3: Electrophysiology Segment - J&J's electrophysiology unit reported a year-over-year sales growth of 7%, totaling $5.63 billion, although growth has slowed in the fourth quarter compared to earlier quarters [5] - The Varipulse PFA system has been utilized in nearly 40,000 patients with atrial fibrillation, indicating significant adoption, and J&J plans to release a new PFA catheter annually through the end of the decade [6] - Schmid emphasized that electrophysiology remains a priority for J&J, as the company aims to remain competitive in the face of increasing competition, particularly in pulsed field ablation (PFA) [6]

Group 1 - Kenvue Inc. is receiving institutional support for its proposed merger with Kimberly-Clark, which is valued at $40 billion, as recommended by Institutional Shareholder Services (ISS) [2] - The merger is expected to create positive synergies and advance strategic objectives, despite ongoing talcum litigation and concerns regarding Tylenol's active ingredient [2] - Meridian Hedged Equity Fund believes the market has overreacted to Tylenol safety concerns, noting minimal revenue impact and a lack of new scientific evidence [3] Group 2 - Kenvue's share price has decreased by 35% since its public listing in 2023, while Kimberly-Clark's share price has dropped by 17% since the merger announcement [4] - Kenvue focuses on consumer healthcare products, operating in Self Care, Skin Health, and Essential Health segments globally [4]

Market Overview - The U.S. stock market experienced significant declines, with over 70.7% of U.S. issues falling on Tuesday, while only 26.4% advanced [2] - The Nasdaq Composite and S&P 500 dropped by 2.39% and 2.06% respectively, with the Dow and Russell 2000 also showing losses of 1.76% and 1.20% [3] Earnings Reports - Major earnings reports expected today include Johnson & Johnson, Charles Schwab, and Prologis, with a focus on regional banks reporting in both premarket and aftermarket sessions [5] - The S&P Regional Bank ETF ($KRE) is anticipated to be particularly responsive to these reports, having risen over 14% since its lows in November 2025 [6]

格隆汇1月21日｜强生(JNJ.US)：第四季度销售额为245.6亿美元，高于预期的241.5亿美元。预计2026财 年运营销售额为995亿至1005亿美元，高于预估的989亿美元。 ...

本文源自：金融界AI电报 强生(JNJ.N)预计2026财年运营销售额为995亿至1005亿美元，高于预估的989亿美元。 ...

Johnson & Johnson on Wednesday forecast 2026 sales and profit ahead of Wall Street estimates, even when including a hit of "hundreds of millions of dollars" from the drug pricing deal it signed with... ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

The healthcare company's forecast for 2026 tops Wall Street's expectations. ...